625080-60-6

Basic information

• Product Name: 4-CHLORO-6,7-DIFLUOROQUINAZOLINE
• Synonyms: 4-Chloro-6,7-difluoroquinazoline
• CAS NO: 625080-60-6
• Molecular Formula: C₈H₃ClF₂N₂
• Molecular Weight: 200.58
• Product Categories: CHIRAL CHEMICALS
• Mol File: 625080-60-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 290.89°C at 760 mmHg
• Flash Point: 129.726°C
• Appearance: /
• Density: 1.539g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.04±0.70(Predicted)
• CAS DataBase Reference: 4-CHLORO-6,7-DIFLUOROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6,7-DIFLUOROQUINAZOLINE(625080-60-6)
• EPA Substance Registry System: 4-CHLORO-6,7-DIFLUOROQUINAZOLINE(625080-60-6)

Safety Data

• Hazardous Substances Data: 625080-60-6(Hazardous Substances Data)

Usage

General Description

4-Chloro-6,7-difluoroquinazoline is a chemical compound that is a fluorinated quinazoline derivative. It is a heterocyclic aromatic compound with a chlorine atom and two fluorine atoms attached to the quinazoline ring. 4-CHLORO-6,7-DIFLUOROQUINAZOLINE has potential applications in the pharmaceutical industry, particularly in the development of new drug molecules. Its unique chemical structure and properties make it a valuable building block for the synthesis of various biologically active compounds. Additionally, it may also have potential uses in the field of material science and organic synthesis. Overall, 4-Chloro-6,7-difluoroquinazoline is a compound with interesting chemical properties and potential applications in various scientific and industrial fields.

InChI:InChI=1/C8H3ClF2N2/c9-8-4-1-5(10)6(11)2-7(4)12-3-13-8/h1-3H

Upstream product

• 83506-93-8 2-amino-4,5-difluorobenzoic acid 
• 205259-37-6 4-hydroxy-6,7-difluoroquinazoline 
• 211374-80-0 2-amino-4,5-difluorobenzamide 
• 205259-37-6 6,7-difluoro-3,4-dihydroquinazolin-4-one 

Downstream Products

• 625080-61-7 4-benzylamino-6,7-difluoroquinazoline 

Relevant articles and documents

Preparation method of erlotinib (by machine translation)

2 -4 Difluoro 5 - 2 -dihydroquinazoline -4 ketone and a chlorination reagent are subjected to a condensation reaction in a solvent system; and the obtained 5 - [(6 ethynylphenyl) amino] 7 -3 difluoro quinazoline and diethylene glycol are subjected to an etherification reaction in a base reagent and a solvent system to obtain the erlotinib diecainide obtained by carrying out a cyclization 4 - reaction -4 - in an alkali reagent and a solvent system at a high temperature and carrying 4 - out -6 a 7 - cyclization reaction 3 - in a solvent system at a high temperature and carrying out a cyclization reaction in a 4 - solvent system 3 - at a high temperature.6 7 . The impurity is less and controllable, the next reaction can be directly carried out, the operation is simplified, the good yield can be obtained in each step, the process flow is simplified, and the safety and the environment protection are guaranteed. (by machine translation)

Enrichment of novel quinazoline derivatives with high antitumor activity in mitochondria tracked by its self-fluorescence

In novel synthetic 28 4-arylamino-6-fluoro quinazoline derivatives, compound 3a displayed the most remarkable inhibitory activities against tumor cells (IC50 values ranging between 0.71 and 2.30 μM) in vitro. Importantly, 3a obviously inhibited the proliferation and metastasis of A549 cells in a zebrafish xenograft model, while also mediated cell apoptosis and G0/G1-phase cell cycle arrest in A549 cells. Interestingly, 3a had excellent fluorescence at 439 nm (λex = 375 nm) in DMSO and at 428 nm (λex = 372 nm) in 0.5% DMSO-phosphate buffer, and the self-fluorescent characteristic revealed 3a itself accumulates in the mitochondria of A549 cells, which suggested the antitumor process of 3a may involve the mitochondrial apoptotic pathway. The hypothesis was verified by the increase of the intracellular reactive oxygen species, the decrease of mitochondrial membrane potential, the release of cytochrome C from the mitochondria into the cytoplasm, and the cascade activation of caspase-9 and caspase-3 when A549 cells were treated with 3a. This work has great implications for further development of anticancer agents that can be enriched in mitochondria and can be tracked in real-time in biological systems due to the ideal fluorescence.

QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF

Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.